title: Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13.
abstract: The clinical manifestations of allergic asthma are believed to result from a dysregulated, T helper 2 lymphocyte (Th2)-biased response to antigen. Although asthma symptoms can be controlled acutely, there is a need for a therapy that will address the underlying immune dysfunction and provide continuous control of chronic airway inflammation. The Th2-type cytokines, IL-13 and IL-4, have been demonstrated to play a crucial role in asthma pathogenesis and their selective neutralization results in the alleviation of asthmatic symptoms in mouse models. The activity of both of these cytokines can be inhibited by a mutant IL-4 protein, IL-4 receptor antagonist (IL-4RA), and thus, continual IL-4RA therapy might be beneficial in treatment of chronic asthma. To explore the potential utility of long-term gene therapy for the treatment of asthma we used a recombinant adeno-associated virus (AAV) vector to deliver and provide sustained expression of IL-4RA in vivo. We show that AAV-mediated delivery of IL-4RA to the airways of mice reduces airway hyperresponsiveness (AHR) and airway eosinophilia triggered by either IL-13 or IL-4. Furthermore, AAV-delivered IL-4RA, expressed either systemically or in the airways of mice following allergen sensitization, significantly inhibited development of airway eosinophilia and mucus production and reduced the levels of asthma-associated Th2 cytokines and AHR in the experimental mouse model of allergic asthma. Thus, gene therapy can be a potential therapeutic option to treat and control chronic airway inflammation and asthmatic symptoms.
authors.affiliation: Bayer Biotechnology, 800 Dwight Way, Berkeley, CA 94710, USA.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Zavorotinskaya
authors.forename: Adrian
authors.initials: A
authors.lastname: Tomkinson
authors.forename: John E
authors.initials: JE
authors.lastname: Murphy
mesh_terms: D000818:Animals; D001249:Asthma / Q000628:therapy*; D000229:Dependovirus / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D007150:Immunohistochemistry; D018793:Interleukin-13 / Q000235:genetics*; D015847:Interleukin-4 / Q000235:genetics*; D016210:Methacholine Chloride / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000378:metabolism; D019948:Receptors, Interleukin-4 / Q000235:genetics; D011994:Recombinant Proteins / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology; D013997:Time Factors
chemical_list: D018793:Interleukin-13; D019948:Receptors, Interleukin-4; D011994:Recombinant Proteins; D016210:Methacholine Chloride; D015847:Interleukin-4